Cyclo Therapeutics, Inc.

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, TAK has a market cap of 52.5B. Regarding current trading prices, CYTH is priced at $0.72, while TAK trades at $16.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas TAK's P/E ratio is 75.59. In terms of profitability, CYTH's ROE is -7.30%, compared to TAK's ROE of +0.02%. Regarding short-term risk, CYTH is less volatile compared to TAK. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check TAK's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, ZTS has a market cap of 49.3B. Regarding current trading prices, CYTH is priced at $0.72, while ZTS trades at $116.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas ZTS's P/E ratio is 19.41. In terms of profitability, CYTH's ROE is -7.30%, compared to ZTS's ROE of +0.58%. Regarding short-term risk, CYTH is less volatile compared to ZTS. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check ZTS's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, HLN has a market cap of 42.7B. Regarding current trading prices, CYTH is priced at $0.72, while HLN trades at $9.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas HLN's P/E ratio is 19.16. In terms of profitability, CYTH's ROE is -7.30%, compared to HLN's ROE of +0.17%. Regarding short-term risk, CYTH is less volatile compared to HLN. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check HLN's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, TEVA has a market cap of 35.7B. Regarding current trading prices, CYTH is priced at $0.72, while TEVA trades at $30.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas TEVA's P/E ratio is 25.32. In terms of profitability, CYTH's ROE is -7.30%, compared to TEVA's ROE of +0.20%. Regarding short-term risk, CYTH is less volatile compared to TEVA. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check TEVA's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, VTRS has a market cap of 17B. Regarding current trading prices, CYTH is priced at $0.72, while VTRS trades at $14.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas VTRS's P/E ratio is -4.86. In terms of profitability, CYTH's ROE is -7.30%, compared to VTRS's ROE of -0.23%. Regarding short-term risk, CYTH is less volatile compared to VTRS. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check VTRS's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, CYTH is priced at $0.72, while ITCI trades at $131.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas ITCI's P/E ratio is -180.64. In terms of profitability, CYTH's ROE is -7.30%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, CYTH and ITCI have similar daily volatility (0.00).Check ITCI's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, RGC has a market cap of 13.6B. Regarding current trading prices, CYTH is priced at $0.72, while RGC trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas RGC's P/E ratio is -2749.00. In terms of profitability, CYTH's ROE is -7.30%, compared to RGC's ROE of -0.62%. Regarding short-term risk, CYTH is less volatile compared to RGC. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check RGC's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, NBIX has a market cap of 12.8B. Regarding current trading prices, CYTH is priced at $0.72, while NBIX trades at $127.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas NBIX's P/E ratio is 27.29. In terms of profitability, CYTH's ROE is -7.30%, compared to NBIX's ROE of +0.17%. Regarding short-term risk, CYTH is less volatile compared to NBIX. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check NBIX's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, CYTH is priced at $0.72, while CTLT trades at $63.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas CTLT's P/E ratio is -27.84. In terms of profitability, CYTH's ROE is -7.30%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, CYTH is less volatile compared to CTLT. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check CTLT's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, RDY has a market cap of 11.4B. Regarding current trading prices, CYTH is priced at $0.72, while RDY trades at $13.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas RDY's P/E ratio is 18.72. In terms of profitability, CYTH's ROE is -7.30%, compared to RDY's ROE of +0.16%. Regarding short-term risk, CYTH is less volatile compared to RDY. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check RDY's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, ELAN has a market cap of 11.4B. Regarding current trading prices, CYTH is priced at $0.72, while ELAN trades at $22.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas ELAN's P/E ratio is -48.39. In terms of profitability, CYTH's ROE is -7.30%, compared to ELAN's ROE of -0.04%. Regarding short-term risk, CYTH is less volatile compared to ELAN. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check ELAN's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, LNTH has a market cap of 5.5B. Regarding current trading prices, CYTH is priced at $0.72, while LNTH trades at $84.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas LNTH's P/E ratio is 24.73. In terms of profitability, CYTH's ROE is -7.30%, compared to LNTH's ROE of +0.21%. Regarding short-term risk, CYTH is less volatile compared to LNTH. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check LNTH's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, INDV has a market cap of 4.1B. Regarding current trading prices, CYTH is priced at $0.72, while INDV trades at $33.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas INDV's P/E ratio is 20.26. In terms of profitability, CYTH's ROE is -7.30%, compared to INDV's ROE of -0.99%. Regarding short-term risk, CYTH is less volatile compared to INDV. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check INDV's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, AMRX has a market cap of 4B. Regarding current trading prices, CYTH is priced at $0.72, while AMRX trades at $12.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas AMRX's P/E ratio is 56.91. In terms of profitability, CYTH's ROE is -7.30%, compared to AMRX's ROE of -0.42%. Regarding short-term risk, CYTH is less volatile compared to AMRX. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check AMRX's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, SUPN has a market cap of 2.9B. Regarding current trading prices, CYTH is priced at $0.72, while SUPN trades at $49.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas SUPN's P/E ratio is -73.06. In terms of profitability, CYTH's ROE is -7.30%, compared to SUPN's ROE of -0.04%. Regarding short-term risk, CYTH is less volatile compared to SUPN. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check SUPN's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, HCM has a market cap of 2.4B. Regarding current trading prices, CYTH is priced at $0.72, while HCM trades at $14.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas HCM's P/E ratio is 5.28. In terms of profitability, CYTH's ROE is -7.30%, compared to HCM's ROE of +0.41%. Regarding short-term risk, CYTH is less volatile compared to HCM. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check HCM's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, PAHC has a market cap of 2.2B. Regarding current trading prices, CYTH is priced at $0.72, while PAHC trades at $55.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas PAHC's P/E ratio is 24.41. In terms of profitability, CYTH's ROE is -7.30%, compared to PAHC's ROE of +0.31%. Regarding short-term risk, CYTH is less volatile compared to PAHC. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check PAHC's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, CYTH is priced at $0.72, while DCPH trades at $25.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas DCPH's P/E ratio is -11.58. In terms of profitability, CYTH's ROE is -7.30%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, CYTH is less volatile compared to DCPH. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check DCPH's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, CYTH is priced at $0.72, while AVDL trades at $21.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, CYTH's ROE is -7.30%, compared to AVDL's ROE of -0.00%. Regarding short-term risk, CYTH and AVDL have similar daily volatility (0.00).Check AVDL's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, BHC has a market cap of 2.1B. Regarding current trading prices, CYTH is priced at $0.72, while BHC trades at $5.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas BHC's P/E ratio is 13.39. In terms of profitability, CYTH's ROE is -7.30%, compared to BHC's ROE of -0.20%. Regarding short-term risk, CYTH is less volatile compared to BHC. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check BHC's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, CYTH is priced at $0.72, while EMBCV trades at $33.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas EMBCV's P/E ratio is N/A. In terms of profitability, CYTH's ROE is -7.30%, compared to EMBCV's ROE of -0.28%. Regarding short-term risk, CYTH is less volatile compared to EMBCV. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check EMBCV's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, CYTH is priced at $0.72, while DVAX trades at $15.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas DVAX's P/E ratio is -41.89. In terms of profitability, CYTH's ROE is -7.30%, compared to DVAX's ROE of -0.08%. Regarding short-term risk, CYTH and DVAX have similar daily volatility (0.00).Check DVAX's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, ANIP has a market cap of 1.8B. Regarding current trading prices, CYTH is priced at $0.72, while ANIP trades at $78.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas ANIP's P/E ratio is 23.69. In terms of profitability, CYTH's ROE is -7.30%, compared to ANIP's ROE of +0.16%. Regarding short-term risk, CYTH is less volatile compared to ANIP. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check ANIP's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, PRGO has a market cap of 1.6B. Regarding current trading prices, CYTH is priced at $0.72, while PRGO trades at $11.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas PRGO's P/E ratio is -1.17. In terms of profitability, CYTH's ROE is -7.30%, compared to PRGO's ROE of -0.35%. Regarding short-term risk, CYTH is less volatile compared to PRGO. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check PRGO's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, CYTH is priced at $0.72, while TARO trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas TARO's P/E ratio is 30.05. In terms of profitability, CYTH's ROE is -7.30%, compared to TARO's ROE of +0.03%. Regarding short-term risk, CYTH is less volatile compared to TARO. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check TARO's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, HROW has a market cap of 1.5B. Regarding current trading prices, CYTH is priced at $0.72, while HROW trades at $39.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas HROW's P/E ratio is -283.57. In terms of profitability, CYTH's ROE is -7.30%, compared to HROW's ROE of -0.10%. Regarding short-term risk, CYTH is less volatile compared to HROW. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check HROW's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, EVO has a market cap of 1.1B. Regarding current trading prices, CYTH is priced at $0.72, while EVO trades at $3.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas EVO's P/E ratio is -9.26. In terms of profitability, CYTH's ROE is -7.30%, compared to EVO's ROE of -0.12%. Regarding short-term risk, CYTH is less volatile compared to EVO. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check EVO's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, ALVO has a market cap of 1.1B. Regarding current trading prices, CYTH is priced at $0.72, while ALVO trades at $3.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas ALVO's P/E ratio is 33.80. In terms of profitability, CYTH's ROE is -7.30%, compared to ALVO's ROE of -0.12%. Regarding short-term risk, CYTH is less volatile compared to ALVO. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check ALVO's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, PCRX has a market cap of 1.1B. Regarding current trading prices, CYTH is priced at $0.72, while PCRX trades at $24.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas PCRX's P/E ratio is 153.19. In terms of profitability, CYTH's ROE is -7.30%, compared to PCRX's ROE of +0.01%. Regarding short-term risk, CYTH is less volatile compared to PCRX. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check PCRX's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, COLL has a market cap of 1B. Regarding current trading prices, CYTH is priced at $0.72, while COLL trades at $32.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas COLL's P/E ratio is 18.79. In terms of profitability, CYTH's ROE is -7.30%, compared to COLL's ROE of +0.24%. Regarding short-term risk, CYTH is less volatile compared to COLL. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check COLL's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, CRON has a market cap of 1B. Regarding current trading prices, CYTH is priced at $0.72, while CRON trades at $2.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas CRON's P/E ratio is -134.00. In terms of profitability, CYTH's ROE is -7.30%, compared to CRON's ROE of -0.01%. Regarding short-term risk, CYTH is less volatile compared to CRON. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check CRON's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, AMPH has a market cap of 971.4M. Regarding current trading prices, CYTH is priced at $0.72, while AMPH trades at $21.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas AMPH's P/E ratio is 10.55. In terms of profitability, CYTH's ROE is -7.30%, compared to AMPH's ROE of +0.13%. Regarding short-term risk, CYTH is less volatile compared to AMPH. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check AMPH's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, CYTH is priced at $0.72, while PETQ trades at $30.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas PETQ's P/E ratio is 83.73. In terms of profitability, CYTH's ROE is -7.30%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, CYTH is less volatile compared to PETQ. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check PETQ's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, TLRY has a market cap of 786.7M. Regarding current trading prices, CYTH is priced at $0.72, while TLRY trades at $6.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas TLRY's P/E ratio is -0.46. In terms of profitability, CYTH's ROE is -7.30%, compared to TLRY's ROE of -0.93%. Regarding short-term risk, CYTH is less volatile compared to TLRY. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check TLRY's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, IRWD has a market cap of 640.8M. Regarding current trading prices, CYTH is priced at $0.72, while IRWD trades at $3.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas IRWD's P/E ratio is 26.20. In terms of profitability, CYTH's ROE is -7.30%, compared to IRWD's ROE of -0.08%. Regarding short-term risk, CYTH is less volatile compared to IRWD. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check IRWD's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, CYTH is priced at $0.72, while BDSI trades at $5.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas BDSI's P/E ratio is 6.82. In terms of profitability, CYTH's ROE is -7.30%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, CYTH is less volatile compared to BDSI. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check BDSI's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, EMBC has a market cap of 546M. Regarding current trading prices, CYTH is priced at $0.72, while EMBC trades at $9.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas EMBC's P/E ratio is 3.91. In terms of profitability, CYTH's ROE is -7.30%, compared to EMBC's ROE of -0.21%. Regarding short-term risk, CYTH is less volatile compared to EMBC. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check EMBC's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, CGC has a market cap of 532.2M. Regarding current trading prices, CYTH is priced at $0.72, while CGC trades at $1.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas CGC's P/E ratio is -0.88. In terms of profitability, CYTH's ROE is -7.30%, compared to CGC's ROE of -0.53%. Regarding short-term risk, CYTH is less volatile compared to CGC. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check CGC's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, KMDA has a market cap of 477.6M. Regarding current trading prices, CYTH is priced at $0.72, while KMDA trades at $8.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas KMDA's P/E ratio is 23.66. In terms of profitability, CYTH's ROE is -7.30%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, CYTH is less volatile compared to KMDA. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check KMDA's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, EBS has a market cap of 415.7M. Regarding current trading prices, CYTH is priced at $0.72, while EBS trades at $8.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas EBS's P/E ratio is 8.63. In terms of profitability, CYTH's ROE is -7.30%, compared to EBS's ROE of +0.10%. Regarding short-term risk, CYTH is less volatile compared to EBS. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check EBS's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, AQST has a market cap of 405.2M. Regarding current trading prices, CYTH is priced at $0.72, while AQST trades at $4.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas AQST's P/E ratio is -5.23. In terms of profitability, CYTH's ROE is -7.30%, compared to AQST's ROE of +1.96%. Regarding short-term risk, CYTH is less volatile compared to AQST. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check AQST's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, ESPR has a market cap of 397.1M. Regarding current trading prices, CYTH is priced at $0.72, while ESPR trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas ESPR's P/E ratio is -17.36. In terms of profitability, CYTH's ROE is -7.30%, compared to ESPR's ROE of +0.06%. Regarding short-term risk, CYTH is less volatile compared to ESPR. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check ESPR's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, SNDL has a market cap of 391.4M. Regarding current trading prices, CYTH is priced at $0.72, while SNDL trades at $1.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas SNDL's P/E ratio is -37.75. In terms of profitability, CYTH's ROE is -7.30%, compared to SNDL's ROE of -0.01%. Regarding short-term risk, CYTH is less volatile compared to SNDL. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check SNDL's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, EOLS has a market cap of 344.8M. Regarding current trading prices, CYTH is priced at $0.72, while EOLS trades at $5.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas EOLS's P/E ratio is -6.62. In terms of profitability, CYTH's ROE is -7.30%, compared to EOLS's ROE of +2.68%. Regarding short-term risk, CYTH is less volatile compared to EOLS. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check EOLS's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, SIGA has a market cap of 327.4M. Regarding current trading prices, CYTH is priced at $0.72, while SIGA trades at $4.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas SIGA's P/E ratio is 14.28. In terms of profitability, CYTH's ROE is -7.30%, compared to SIGA's ROE of +0.11%. Regarding short-term risk, CYTH is less volatile compared to SIGA. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check SIGA's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, ORGO has a market cap of 302.3M. Regarding current trading prices, CYTH is priced at $0.72, while ORGO trades at $2.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas ORGO's P/E ratio is 15.67. In terms of profitability, CYTH's ROE is -7.30%, compared to ORGO's ROE of +0.10%. Regarding short-term risk, CYTH is less volatile compared to ORGO. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check ORGO's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, CYTH is priced at $0.72, while ALIM trades at $5.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas ALIM's P/E ratio is 5.28. In terms of profitability, CYTH's ROE is -7.30%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, CYTH is less volatile compared to ALIM. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check ALIM's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, CYTH is priced at $0.72, while LNDC trades at $8.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas LNDC's P/E ratio is -4.04. In terms of profitability, CYTH's ROE is -7.30%, compared to LNDC's ROE of -14.63%. Regarding short-term risk, CYTH is less volatile compared to LNDC. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check LNDC's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, CYTH is priced at $0.72, while TYHT trades at $11.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas TYHT's P/E ratio is -1.61. In terms of profitability, CYTH's ROE is -7.30%, compared to TYHT's ROE of -0.65%. Regarding short-term risk, CYTH is less volatile compared to TYHT. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check TYHT's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, OGI has a market cap of 197M. Regarding current trading prices, CYTH is priced at $0.72, while OGI trades at $1.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas OGI's P/E ratio is 13.14. In terms of profitability, CYTH's ROE is -7.30%, compared to OGI's ROE of +0.05%. Regarding short-term risk, CYTH is less volatile compared to OGI. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check OGI's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, ACB has a market cap of 192.2M. Regarding current trading prices, CYTH is priced at $0.72, while ACB trades at $3.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas ACB's P/E ratio is -3.11. In terms of profitability, CYTH's ROE is -7.30%, compared to ACB's ROE of -0.08%. Regarding short-term risk, CYTH is less volatile compared to ACB. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check ACB's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, LFCR has a market cap of 188.1M. Regarding current trading prices, CYTH is priced at $0.72, while LFCR trades at $5.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas LFCR's P/E ratio is -3.95. In terms of profitability, CYTH's ROE is -7.30%, compared to LFCR's ROE of -1.82%. Regarding short-term risk, CYTH is less volatile compared to LFCR. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check LFCR's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, CYTH is priced at $0.72, while REPH trades at $2.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas REPH's P/E ratio is -8.04. In terms of profitability, CYTH's ROE is -7.30%, compared to REPH's ROE of -0.22%. Regarding short-term risk, CYTH is less volatile compared to REPH. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check REPH's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, TKNO has a market cap of 170.4M. Regarding current trading prices, CYTH is priced at $0.72, while TKNO trades at $3.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas TKNO's P/E ratio is -9.94. In terms of profitability, CYTH's ROE is -7.30%, compared to TKNO's ROE of -0.23%. Regarding short-term risk, CYTH is less volatile compared to TKNO. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check TKNO's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, CRDL has a market cap of 156.4M. Regarding current trading prices, CYTH is priced at $0.72, while CRDL trades at $1.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas CRDL's P/E ratio is -4.83. In terms of profitability, CYTH's ROE is -7.30%, compared to CRDL's ROE of -2.38%. Regarding short-term risk, CYTH is less volatile compared to CRDL. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check CRDL's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, CYTH is priced at $0.72, while THTX trades at $3.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas THTX's P/E ratio is -17.84. In terms of profitability, CYTH's ROE is -7.30%, compared to THTX's ROE of +0.47%. Regarding short-term risk, CYTH is less volatile compared to THTX. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check THTX's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, DERM has a market cap of 126.2M. Regarding current trading prices, CYTH is priced at $0.72, while DERM trades at $5.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas DERM's P/E ratio is -10.96. In terms of profitability, CYTH's ROE is -7.30%, compared to DERM's ROE of -0.46%. Regarding short-term risk, CYTH is less volatile compared to DERM. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check DERM's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, ASRT has a market cap of 116.3M. Regarding current trading prices, CYTH is priced at $0.72, while ASRT trades at $18.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas ASRT's P/E ratio is -3.81. In terms of profitability, CYTH's ROE is -7.30%, compared to ASRT's ROE of -0.29%. Regarding short-term risk, CYTH is less volatile compared to ASRT. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check ASRT's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, CYTH is priced at $0.72, while SCTL trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas SCTL's P/E ratio is -7.86. In terms of profitability, CYTH's ROE is -7.30%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, CYTH is less volatile compared to SCTL. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check SCTL's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, CYTH is priced at $0.72, while PROC trades at $1.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas PROC's P/E ratio is 1.53. In terms of profitability, CYTH's ROE is -7.30%, compared to PROC's ROE of -2.22%. Regarding short-term risk, CYTH and PROC have similar daily volatility (0.00).Check PROC's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, CYTH is priced at $0.72, while OPTN trades at $9.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas OPTN's P/E ratio is -4.42. In terms of profitability, CYTH's ROE is -7.30%, compared to OPTN's ROE of +0.45%. Regarding short-term risk, CYTH and OPTN have similar daily volatility (0.00).Check OPTN's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, CYTH is priced at $0.72, while ZOM trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas ZOM's P/E ratio is -1.62. In terms of profitability, CYTH's ROE is -7.30%, compared to ZOM's ROE of -0.66%. Regarding short-term risk, CYTH is less volatile compared to ZOM. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check ZOM's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, CYTH is priced at $0.72, while GRVI trades at $4.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas GRVI's P/E ratio is 26.05. In terms of profitability, CYTH's ROE is -7.30%, compared to GRVI's ROE of -1.20%. Regarding short-term risk, CYTH is less volatile compared to GRVI. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check GRVI's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, CYTH is priced at $0.72, while ZYNE trades at $1.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, CYTH's ROE is -7.30%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, CYTH is less volatile compared to ZYNE. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check ZYNE's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, ALVOW has a market cap of 66.9M. Regarding current trading prices, CYTH is priced at $0.72, while ALVOW trades at $0.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas ALVOW's P/E ratio is N/A. In terms of profitability, CYTH's ROE is -7.30%, compared to ALVOW's ROE of -0.12%. Regarding short-term risk, CYTH is less volatile compared to ALVOW. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check ALVOW's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, BGM has a market cap of 66.8M. Regarding current trading prices, CYTH is priced at $0.72, while BGM trades at $0.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas BGM's P/E ratio is -1.15. In terms of profitability, CYTH's ROE is -7.30%, compared to BGM's ROE of -0.03%. Regarding short-term risk, CYTH is less volatile compared to BGM. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check BGM's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, CYTH is priced at $0.72, while SSIC trades at $10.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas SSIC's P/E ratio is 11.93. In terms of profitability, CYTH's ROE is -7.30%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, CYTH is less volatile compared to SSIC. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check SSIC's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, CYTH is priced at $0.72, while VLNS trades at $0.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas VLNS's P/E ratio is -1.03. In terms of profitability, CYTH's ROE is -7.30%, compared to VLNS's ROE of N/A. Regarding short-term risk, CYTH is less volatile compared to VLNS. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check VLNS's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, CPIX has a market cap of 60.7M. Regarding current trading prices, CYTH is priced at $0.72, while CPIX trades at $4.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas CPIX's P/E ratio is -21.37. In terms of profitability, CYTH's ROE is -7.30%, compared to CPIX's ROE of -0.11%. Regarding short-term risk, CYTH is less volatile compared to CPIX. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check CPIX's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, CYTH is priced at $0.72, while DRRX trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas DRRX's P/E ratio is -4.44. In terms of profitability, CYTH's ROE is -7.30%, compared to DRRX's ROE of +0.13%. Regarding short-term risk, CYTH and DRRX have similar daily volatility (0.00).Check DRRX's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, INCR has a market cap of 50.3M. Regarding current trading prices, CYTH is priced at $0.72, while INCR trades at $0.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas INCR's P/E ratio is -1.80. In terms of profitability, CYTH's ROE is -7.30%, compared to INCR's ROE of -0.09%. Regarding short-term risk, CYTH is less volatile compared to INCR. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check INCR's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, CYTH is priced at $0.72, while JUPW trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas JUPW's P/E ratio is -2.41. In terms of profitability, CYTH's ROE is -7.30%, compared to JUPW's ROE of -2.05%. Regarding short-term risk, CYTH is less volatile compared to JUPW. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check JUPW's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, IXHL has a market cap of 46.3M. Regarding current trading prices, CYTH is priced at $0.72, while IXHL trades at $4.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas IXHL's P/E ratio is -0.18. In terms of profitability, CYTH's ROE is -7.30%, compared to IXHL's ROE of -1.99%. Regarding short-term risk, CYTH is less volatile compared to IXHL. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check IXHL's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, SCYX has a market cap of 45.6M. Regarding current trading prices, CYTH is priced at $0.72, while SCYX trades at $1.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas SCYX's P/E ratio is -6.00. In terms of profitability, CYTH's ROE is -7.30%, compared to SCYX's ROE of -0.19%. Regarding short-term risk, CYTH is less volatile compared to SCYX. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check SCYX's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, ZYBT has a market cap of 42.7M. Regarding current trading prices, CYTH is priced at $0.72, while ZYBT trades at $0.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas ZYBT's P/E ratio is -15.00. In terms of profitability, CYTH's ROE is -7.30%, compared to ZYBT's ROE of +0.04%. Regarding short-term risk, CYTH is less volatile compared to ZYBT. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check ZYBT's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, CYTH is priced at $0.72, while QLI trades at $5.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas QLI's P/E ratio is -4.92. In terms of profitability, CYTH's ROE is -7.30%, compared to QLI's ROE of -0.16%. Regarding short-term risk, CYTH and QLI have similar daily volatility (0.00).Check QLI's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, RMTI has a market cap of 34.4M. Regarding current trading prices, CYTH is priced at $0.72, while RMTI trades at $0.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas RMTI's P/E ratio is -5.82. In terms of profitability, CYTH's ROE is -7.30%, compared to RMTI's ROE of -0.16%. Regarding short-term risk, CYTH is less volatile compared to RMTI. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check RMTI's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, CYTH is priced at $0.72, while HEXO trades at $0.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas HEXO's P/E ratio is -0.26. In terms of profitability, CYTH's ROE is -7.30%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, CYTH is less volatile compared to HEXO. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check HEXO's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, TXMD has a market cap of 24.5M. Regarding current trading prices, CYTH is priced at $0.72, while TXMD trades at $2.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas TXMD's P/E ratio is -35.33. In terms of profitability, CYTH's ROE is -7.30%, compared to TXMD's ROE of -0.02%. Regarding short-term risk, CYTH is less volatile compared to TXMD. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check TXMD's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, AYTU has a market cap of 20.4M. Regarding current trading prices, CYTH is priced at $0.72, while AYTU trades at $2.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas AYTU's P/E ratio is -0.73. In terms of profitability, CYTH's ROE is -7.30%, compared to AYTU's ROE of -1.07%. Regarding short-term risk, CYTH is less volatile compared to AYTU. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check AYTU's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, CYTH is priced at $0.72, while EVOK trades at $11.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas EVOK's P/E ratio is -7.97. In terms of profitability, CYTH's ROE is -7.30%, compared to EVOK's ROE of -1.01%. Regarding short-term risk, CYTH and EVOK have similar daily volatility (0.00).Check EVOK's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, TLPH has a market cap of 15.7M. Regarding current trading prices, CYTH is priced at $0.72, while TLPH trades at $0.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas TLPH's P/E ratio is -2.26. In terms of profitability, CYTH's ROE is -7.30%, compared to TLPH's ROE of -1.18%. Regarding short-term risk, CYTH is less volatile compared to TLPH. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check TLPH's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, QNTM has a market cap of 14.9M. Regarding current trading prices, CYTH is priced at $0.72, while QNTM trades at $3.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas QNTM's P/E ratio is -0.44. In terms of profitability, CYTH's ROE is -7.30%, compared to QNTM's ROE of -4.19%. Regarding short-term risk, CYTH is less volatile compared to QNTM. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check QNTM's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, CYTH is priced at $0.72, while ACRX trades at $0.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas ACRX's P/E ratio is -0.31. In terms of profitability, CYTH's ROE is -7.30%, compared to ACRX's ROE of -1.18%. Regarding short-term risk, CYTH is less volatile compared to ACRX. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check ACRX's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, BFRI has a market cap of 12.6M. Regarding current trading prices, CYTH is priced at $0.72, while BFRI trades at $1.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas BFRI's P/E ratio is -1.04. In terms of profitability, CYTH's ROE is -7.30%, compared to BFRI's ROE of -11.39%. Regarding short-term risk, CYTH is less volatile compared to BFRI. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check BFRI's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, COSM has a market cap of 11.5M. Regarding current trading prices, CYTH is priced at $0.72, while COSM trades at $0.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas COSM's P/E ratio is -0.60. In terms of profitability, CYTH's ROE is -7.30%, compared to COSM's ROE of -0.82%. Regarding short-term risk, CYTH is less volatile compared to COSM. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check COSM's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, YCBD has a market cap of 10.5M. Regarding current trading prices, CYTH is priced at $0.72, while YCBD trades at $1.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas YCBD's P/E ratio is 1.67. In terms of profitability, CYTH's ROE is -7.30%, compared to YCBD's ROE of -0.41%. Regarding short-term risk, CYTH is less volatile compared to YCBD. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check YCBD's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, CYTH is priced at $0.72, while AGRX trades at $1.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas AGRX's P/E ratio is -0.89. In terms of profitability, CYTH's ROE is -7.30%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, CYTH is less volatile compared to AGRX. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check AGRX's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, CYTH is priced at $0.72, while NLTX trades at $3.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas NLTX's P/E ratio is -0.28. In terms of profitability, CYTH's ROE is -7.30%, compared to NLTX's ROE of -0.33%. Regarding short-term risk, CYTH is less volatile compared to NLTX. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check NLTX's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, CYTH is priced at $0.72, while LCI trades at $0.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas LCI's P/E ratio is -0.04. In terms of profitability, CYTH's ROE is -7.30%, compared to LCI's ROE of +1.66%. Regarding short-term risk, CYTH is less volatile compared to LCI. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check LCI's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, BGXX has a market cap of 7.3M. Regarding current trading prices, CYTH is priced at $0.72, while BGXX trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas BGXX's P/E ratio is -0.76. In terms of profitability, CYTH's ROE is -7.30%, compared to BGXX's ROE of -1.16%. Regarding short-term risk, CYTH and BGXX have similar daily volatility (0.00).Check BGXX's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, CYTH is priced at $0.72, while ADMP trades at $0.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas ADMP's P/E ratio is -0.08. In terms of profitability, CYTH's ROE is -7.30%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, CYTH is less volatile compared to ADMP. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check ADMP's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, GELS has a market cap of 6.4M. Regarding current trading prices, CYTH is priced at $0.72, while GELS trades at $0.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas GELS's P/E ratio is -1.35. In terms of profitability, CYTH's ROE is -7.30%, compared to GELS's ROE of -0.43%. Regarding short-term risk, CYTH is less volatile compared to GELS. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check GELS's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, EGRX has a market cap of 4.9M. Regarding current trading prices, CYTH is priced at $0.72, while EGRX trades at $0.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas EGRX's P/E ratio is 5.43. In terms of profitability, CYTH's ROE is -7.30%, compared to EGRX's ROE of +0.17%. Regarding short-term risk, CYTH is less volatile compared to EGRX. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check EGRX's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, SBFM has a market cap of 4.9M. Regarding current trading prices, CYTH is priced at $0.72, while SBFM trades at $1.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas SBFM's P/E ratio is -0.69. In terms of profitability, CYTH's ROE is -7.30%, compared to SBFM's ROE of -0.25%. Regarding short-term risk, CYTH is less volatile compared to SBFM. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check SBFM's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, CYTH is priced at $0.72, while MNK trades at $0.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas MNK's P/E ratio is -0.44. In terms of profitability, CYTH's ROE is -7.30%, compared to MNK's ROE of -0.23%. Regarding short-term risk, CYTH is less volatile compared to MNK. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check MNK's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, CYTH is priced at $0.72, while FLGC trades at $7.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas FLGC's P/E ratio is -0.19. In terms of profitability, CYTH's ROE is -7.30%, compared to FLGC's ROE of -0.12%. Regarding short-term risk, CYTH is less volatile compared to FLGC. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check FLGC's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, GHSI has a market cap of 4.2M. Regarding current trading prices, CYTH is priced at $0.72, while GHSI trades at $3.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas GHSI's P/E ratio is -0.79. In terms of profitability, CYTH's ROE is -7.30%, compared to GHSI's ROE of +0.01%. Regarding short-term risk, CYTH and GHSI have similar daily volatility (0.00).Check GHSI's competition here

CYTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CYTH stands at 23.6M. In comparison, RDHL has a market cap of 3.4M. Regarding current trading prices, CYTH is priced at $0.72, while RDHL trades at $1.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CYTH currently has a P/E ratio of -0.80, whereas RDHL's P/E ratio is N/A. In terms of profitability, CYTH's ROE is -7.30%, compared to RDHL's ROE of +1.49%. Regarding short-term risk, CYTH is less volatile compared to RDHL. This indicates potentially lower risk in terms of short-term price fluctuations for CYTH.Check RDHL's competition here